Dr. Richard S. Bloomfeld, MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- Washington University School of Medicine (1990)
- Years since graduation
- 36
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 179
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1990Medical school: Washington University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
NC license 9600430
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- North Carolina Baptist Hospital Winston-Salem, NC
Medical groups
- Wake Forest University Health Sciences (2,645 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 179
- Services billed
- 252
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 89 | 53 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 31 | 31 |
| Biopsy of large bowel using a flexible endoscope | 27 | 27 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 24 | 24 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 15 | 14 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 15 | 15 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Stelara (ustekinumab) | 142 |
| Ondansetron Odt (ondansetron) Other prescribers in Winston Salem, NC | 42 |
| Mesalamine Er (mesalamine) Other prescribers in Winston Salem, NC | 41 |
| Mesalamine Other prescribers in Winston Salem, NC | 40 |
| Humira(Cf) Pen (adalimumab) Other prescribers in Winston Salem, NC | 33 |
| Skyrizi On-Body (risankizumab-rzaa) | 32 |
| Mercaptopurine | 31 |
| Metronidazole Other prescribers in Winston Salem, NC | 27 |
| Azathioprine Other prescribers in Winston Salem, NC | 22 |
| Humira Pen (adalimumab) Other prescribers in Winston Salem, NC | 22 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 14 payments worth $465 in total to this clinician.
| AbbVie Inc. | $256 |
|---|---|
| Pentax of America, Inc. | $179 |
| Cook Medical LLC | $30.08 |
| Food and Beverage | $465 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 1 companies. The companies reported $29,295 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
AbbVie Inc. · Active, not recruiting · NCT06257875 - A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
AbbVie Inc. · Completed · NCT01848561 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
AbbVie Inc. · Active, not recruiting · NCT03006068 - A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
AbbVie Inc. - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
AbbVie Inc. · Active, not recruiting · NCT03345823 - M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.